Alexander Enk
Alexander Enk is an expert in Dermatology at University Hospital Heidelberg (Germany). As of October 2026, ScienceLeadR ranks Alexander Enk in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Alexander Enk has authored 663 publications, the most recent in 2026, and is an investigator in 8 clinical trials, 1 of them ongoing. SLR score: 1,723 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Immunology - Oncology - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1992 - 2026
Number : 663
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| An anti-PMEL antibody-drug conjugate with a G q/1 1 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial. PMID 42443515 — pharmaceutical preparations, melanoma, neoplasms, therapeutics, uveal melanoma | Nat Med Top journal | 2026 | 2 |
| Robustness of a neural network approved for skin cancer diagnosis against variations in sequential images. PMID 42411020 — skin, melanoma, neoplasms, skin diseases, diagnosis, wounds and injuries, skin neoplasms, dermoscopy | J Dtsch Dermatol Ges | 2026 | 0 |
| [Multiple papules on the thighs in an adult]. PMID 42319424 — skin diseases | Dermatologie (Heidelb) | 2026 | 0 |
| Multiclass convolutional neural network vs. 96 dermatologists in skin lesion diagnosis, an international study. PMID 42252869 — skin, cells, carcinoma, squamous cell, skin diseases, deep learning, diagnosis, dermatologists, carcinoma in situ, dermoscopy | J Dtsch Dermatol Ges | 2026 | 0 |
| Performance of PEN-FAST and CEPH-FAST for Cephalosporin Allergy Delabeling. PMID 42203521 — skin, research design, pharmaceutical preparations, hypersensitivity, drug hypersensitivity, predictive value of tests, skin tests, cephalosporins, allergy | Clin Transl Allergy | 2026 | 0 |
Clinical Studies 8
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Phase I II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ 11 Mutant Melanomas NCT05415072 — eye neoplasms, eye, melanoma, neoplasms, multiple chronic conditions, mutation, uveal melanoma | Phase 1/Phase 2 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map